Redeye provides a research update following the Q2 report published by Alzinova earlier today. The financials in the report contained no major surprises, being overall in line with our expectations. Importantly, Alzinova has now signed a Letter of Intent (LoI) with Fujirebio regarding its emerging blood-based diagnostic program as the company continues preparations ahead of an upcoming phase II study with ALZ-101. Following Redeye's new valuation approach, which factors in both fundamental valuation and relative valuation, we assign Alzinova a new fair value of SEK1.7 per share.
LÄS MER
